FR2479807A1 - Acide 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoique, procedes pour sa preparation et composition therapeutique le contenant - Google Patents
Acide 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoique, procedes pour sa preparation et composition therapeutique le contenant Download PDFInfo
- Publication number
- FR2479807A1 FR2479807A1 FR8106874A FR8106874A FR2479807A1 FR 2479807 A1 FR2479807 A1 FR 2479807A1 FR 8106874 A FR8106874 A FR 8106874A FR 8106874 A FR8106874 A FR 8106874A FR 2479807 A1 FR2479807 A1 FR 2479807A1
- Authority
- FR
- France
- Prior art keywords
- compound
- general formula
- preparation
- formula
- tetramethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000000203 mixture Substances 0.000 title description 10
- UUBHZHZSIKRVIV-KCXSXWJSSA-N (2e,6e,10e)-3,7,11,15-tetramethylhexadeca-2,4,6,10,14-pentaenoic acid Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O UUBHZHZSIKRVIV-KCXSXWJSSA-N 0.000 title description 2
- 230000001225 therapeutic effect Effects 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 83
- 230000003780 keratinization Effects 0.000 claims abstract description 16
- 239000002253 acid Substances 0.000 claims abstract description 10
- 208000017520 skin disease Diseases 0.000 claims abstract description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 230000035943 smell Effects 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- 239000003937 drug carrier Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 238000000862 absorption spectrum Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- WTEVQBCEXWBHNA-YFHOEESVSA-N neral Chemical compound CC(C)=CCC\C(C)=C/C=O WTEVQBCEXWBHNA-YFHOEESVSA-N 0.000 description 6
- -1 trimethyl-4-methoxyphenyl Chemical group 0.000 description 6
- 230000001093 anti-cancer Effects 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 239000012295 chemical reaction liquid Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000024963 hair loss Diseases 0.000 description 4
- 230000003676 hair loss Effects 0.000 description 4
- 201000006122 hypervitaminosis A Diseases 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000003154 papilloma Diseases 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 231100000820 toxicity test Toxicity 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- 229940045997 vitamin a Drugs 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 206010011703 Cyanosis Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 208000037656 Respiratory Sounds Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 206010037833 rales Diseases 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- WTEVQBCEXWBHNA-JXMROGBWSA-N citral A Natural products CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 235000009973 maize Nutrition 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 231100000926 not very toxic Toxicity 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- VSRRYUHUBIVZHZ-FGEFXVFKSA-N (2e,6e,10e)-dodeca-2,6,10-triene Chemical compound C\C=C\CC\C=C\CC\C=C\C VSRRYUHUBIVZHZ-FGEFXVFKSA-N 0.000 description 1
- ISLUUYGEJVSMEL-UHFFFAOYSA-N 12,12-dimethyltrideca-2,6,10-trienal Chemical compound CC(C=CCCC=CCCC=CC=O)(C)C ISLUUYGEJVSMEL-UHFFFAOYSA-N 0.000 description 1
- AGYJQFKQDHBIEQ-UHFFFAOYSA-N 3-diethoxyphosphorylbut-1-ene Chemical compound CCOP(=O)(OCC)C(C)C=C AGYJQFKQDHBIEQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- YSSIQOFSGWBPGN-UHFFFAOYSA-N CC(=C(C(=C(C(=O)OCC)C)C)C)C=CCCC=CCCC=CC Chemical compound CC(=C(C(=C(C(=O)OCC)C)C)C)C=CCCC=CCCC=CC YSSIQOFSGWBPGN-UHFFFAOYSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000002506 Darier Disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- ICMAFTSLXCXHRK-UHFFFAOYSA-N Ethyl pentanoate Chemical compound CCCCC(=O)OCC ICMAFTSLXCXHRK-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 206010023369 Keratosis follicular Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000101040 Pityriasis Species 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940117173 croton oil Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- JIPWHZOYUGYXFA-GQCTYLIASA-N ethyl (e)-4-bromo-3-methylbut-2-enoate Chemical compound CCOC(=O)\C=C(/C)CBr JIPWHZOYUGYXFA-GQCTYLIASA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- XPYGGHVSFMUHLH-UUSULHAXSA-N falecalcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(O)(C(F)(F)F)C(F)(F)F)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C XPYGGHVSFMUHLH-UUSULHAXSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 201000004607 keratosis follicularis Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- DGMKFQYCZXERLX-UHFFFAOYSA-N proglumide Chemical compound CCCN(CCC)C(=O)C(CCC(O)=O)NC(=O)C1=CC=CC=C1 DGMKFQYCZXERLX-UHFFFAOYSA-N 0.000 description 1
- 201000010914 pustulosis of palm and sole Diseases 0.000 description 1
- 208000011797 pustulosis palmaris et plantaris Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4455880A JPS56140949A (en) | 1980-04-07 | 1980-04-07 | 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenic acid |
| JP10442080A JPS5731615A (en) | 1980-07-31 | 1980-07-31 | Remedy for skin disease with keratinization |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2479807A1 true FR2479807A1 (fr) | 1981-10-09 |
| FR2479807B1 FR2479807B1 (ja) | 1984-07-20 |
Family
ID=26384501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8106874A Granted FR2479807A1 (fr) | 1980-04-07 | 1981-04-06 | Acide 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoique, procedes pour sa preparation et composition therapeutique le contenant |
Country Status (11)
| Country | Link |
|---|---|
| AU (1) | AU537402B2 (ja) |
| CA (1) | CA1179370A (ja) |
| CH (1) | CH646682A5 (ja) |
| DE (1) | DE3113149A1 (ja) |
| DK (1) | DK158457C (ja) |
| ES (2) | ES8205190A1 (ja) |
| FR (1) | FR2479807A1 (ja) |
| GB (1) | GB2073750B (ja) |
| IT (1) | IT1194141B (ja) |
| NL (1) | NL191744C (ja) |
| SE (1) | SE447243B (ja) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0054732A1 (en) * | 1980-12-24 | 1982-06-30 | Eisai Co., Ltd. | Conjugated polyprenylcarboxylic acids and their derivatives as well as pharmaceutical preparations containing these compounds |
| EP0059258A1 (en) * | 1980-12-24 | 1982-09-08 | Eisai Co., Ltd. | Pharmaceutical preparations comprising polyprenyl compounds, especially as anti-cancer agents, and pharmaceutical compositions for the prevention and treatment of cancer and skin diseases |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56140949A (en) * | 1980-04-07 | 1981-11-04 | Eisai Co Ltd | 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenic acid |
| JPS58164508A (ja) * | 1982-03-26 | 1983-09-29 | Eisai Co Ltd | イソプレニルカルボン酸含有外用組成物 |
| JPS5973516A (ja) * | 1982-10-21 | 1984-04-25 | Eisai Co Ltd | 抗炎症剤 |
| JPS6160612A (ja) * | 1984-08-31 | 1986-03-28 | Eisai Co Ltd | 制癌効果増強剤 |
| IL107587A (en) * | 1993-11-12 | 1998-08-16 | Univ Ramot | Farnesyl geranyl or geranyl-geranyl derivatives pharmaceutical compositions containing them and methods for their preparation |
| US20050250671A1 (en) | 2000-04-24 | 2005-11-10 | Yoshihiro Shidoji | Activators of peroxisome proliferator-activated receptor |
| CN116041172A (zh) * | 2023-02-01 | 2023-05-02 | 宝鸡文理学院 | 一种神经酸的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2171497A5 (en) * | 1972-02-02 | 1973-09-21 | Rhone Poulenc Sa | 1,5-dimethyl-1,5-hexadienylidene sulphone derivs - - intermediates for terpenes |
| FR2348907A1 (fr) * | 1976-04-24 | 1977-11-18 | Sankyo Co | Derives polyprenyliques,leur procede de preparation et leur application en therapeutique |
-
1981
- 1981-04-01 DE DE19813113149 patent/DE3113149A1/de active Granted
- 1981-04-01 NL NL8101630A patent/NL191744C/xx not_active IP Right Cessation
- 1981-04-01 GB GB8110160A patent/GB2073750B/en not_active Expired
- 1981-04-03 SE SE8102161A patent/SE447243B/sv not_active IP Right Cessation
- 1981-04-06 CH CH231781A patent/CH646682A5/fr not_active IP Right Cessation
- 1981-04-06 ES ES501124A patent/ES8205190A1/es not_active Expired
- 1981-04-06 DK DK155081A patent/DK158457C/da not_active IP Right Cessation
- 1981-04-06 FR FR8106874A patent/FR2479807A1/fr active Granted
- 1981-04-06 CA CA000374715A patent/CA1179370A/en not_active Expired
- 1981-04-07 AU AU69159/81A patent/AU537402B2/en not_active Ceased
- 1981-04-07 IT IT20967/81A patent/IT1194141B/it active
-
1982
- 1982-02-25 ES ES509913A patent/ES8304058A1/es not_active Expired
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2171497A5 (en) * | 1972-02-02 | 1973-09-21 | Rhone Poulenc Sa | 1,5-dimethyl-1,5-hexadienylidene sulphone derivs - - intermediates for terpenes |
| FR2348907A1 (fr) * | 1976-04-24 | 1977-11-18 | Sankyo Co | Derives polyprenyliques,leur procede de preparation et leur application en therapeutique |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0054732A1 (en) * | 1980-12-24 | 1982-06-30 | Eisai Co., Ltd. | Conjugated polyprenylcarboxylic acids and their derivatives as well as pharmaceutical preparations containing these compounds |
| EP0059258A1 (en) * | 1980-12-24 | 1982-09-08 | Eisai Co., Ltd. | Pharmaceutical preparations comprising polyprenyl compounds, especially as anti-cancer agents, and pharmaceutical compositions for the prevention and treatment of cancer and skin diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| SE447243B (sv) | 1986-11-03 |
| DK158457B (da) | 1990-05-21 |
| FR2479807B1 (ja) | 1984-07-20 |
| NL191744C (nl) | 1996-06-04 |
| DK155081A (da) | 1981-10-08 |
| DK158457C (da) | 1990-10-08 |
| GB2073750B (en) | 1984-02-22 |
| NL8101630A (nl) | 1981-11-02 |
| ES501124A0 (es) | 1982-06-01 |
| ES509913A0 (es) | 1983-02-16 |
| ES8304058A1 (es) | 1983-02-16 |
| SE8102161L (sv) | 1981-10-08 |
| GB2073750A (en) | 1981-10-21 |
| IT8120967A0 (it) | 1981-04-07 |
| DE3113149A1 (de) | 1982-01-28 |
| CA1179370A (en) | 1984-12-11 |
| ES8205190A1 (es) | 1982-06-01 |
| AU6915981A (en) | 1981-10-15 |
| DE3113149C2 (ja) | 1988-11-10 |
| AU537402B2 (en) | 1984-06-21 |
| IT1194141B (it) | 1988-09-14 |
| CH646682A5 (fr) | 1984-12-14 |
| NL191744B (nl) | 1996-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0051023B1 (fr) | Nouveaux composés appartenant à la famille des benzoyl- et alpha-hydroxybenzyl-phényl-osides, leur procédé de préparation et leur application en thérapeutique | |
| FR2460914A1 (fr) | Derives quinoniques et leur procede de preparation | |
| CA1313662C (fr) | Esters retinoiques de macrolides, leur procede de preparation et compositions pharmaceutiques et cosmetiques les contenant | |
| CA2185192C (fr) | Nouveaux acides et esters 2,2- dimethyl-w-phenoxy alcanoiques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| FR2479807A1 (fr) | Acide 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoique, procedes pour sa preparation et composition therapeutique le contenant | |
| US4917829A (en) | 3,7,11,15-Tetramethyl-2,4,6,10,14,-hexadecapentaendic acid | |
| KR840001518B1 (ko) | 3,7,11,15-테트라메틸-2,4,6,10,14-헥사데카펜타엔산(酸)의 제조방법 | |
| CA2633225A1 (fr) | Nouveaux composes polyinsatures, leur procede de preparation et les compositions les contenant | |
| EP0054732B1 (en) | Conjugated polyprenylcarboxylic acids and their derivatives as well as pharmaceutical preparations containing these compounds | |
| FR2559488A1 (fr) | Composes d'organogermanium a la fois hydrophiles et lipophiles et procede pour leur production | |
| EP0300844B1 (fr) | Nouveaux glycérides d'acide gras insaturé et leurs procédés d'obtention | |
| FR2510558A1 (fr) | Derives nouveaux d'acide chenodesoxycholique | |
| CA2098185A1 (fr) | Procede de preparation de derives de l'acide dihydroxy-3,5 pentanoique | |
| EP0012072B1 (fr) | Bêta-lactones dérivées de l'acide 2-hydroxy cyclopentane carboxylique, procédé pour leur préparation et compositions pharmaceutiques les renfermant | |
| EP0312412B1 (fr) | Nouveaux dérivés du norbornane, leur procédé de préparation et compositions cosmétique et médicamenteuse les contenant | |
| EP0518722B1 (fr) | Rétinoides substitués par un cycle dithiane et leur utilisation, procédé de préparation desdits composés, compositions cosmétique et pharmaceutique les contenant et utilisation thérapeutique de cette dernière | |
| EP0153203A1 (fr) | Acides gras ramifiés en C10 à C20 utiles en tant que médicaments, et leur procédé de préparation | |
| EP0002635A1 (fr) | Procédé de préparation de dérivés de thiéno (2,3-c) et (3,2-c) pyridines, nouveaux dérivés de la thiéno (2,3-c) pyridine obtenus et leur application thérapeutique | |
| CH640818A5 (fr) | Derives d'acide naphtyl-1 acetique, leurs procedes de preparation et medicament les contenant. | |
| FR2595703A1 (fr) | Nouveaux phospholipides, leur procede et les intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant | |
| EP0580476B1 (fr) | Procédé de fabrication de 6E-leucotriène B4 et produits intermédiaires dudit procédé de fabrication | |
| BE1001109A3 (fr) | Nouvelles prostacyclines. | |
| BE884145R (fr) | Composes indoliques nouveaux | |
| SU897766A1 (ru) | Способ получени арахидоновой кислоты | |
| CA1228365A (fr) | Lactones de l'acide tetra-alkyl-3,3,6,6 hydroxy-6 hexanoique substitue en 4 par un radical alkyl ou aryl sulfonate, et leur procede de preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |